newsfilter
← Latest News
PR Newswire·

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics, Inc. (NASDAQ: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology...